Cell-cycle inhibitors for the treatment of cancer

Drugs of the Future

Volumn 28, Issue 9, 2003, Pages 881-896

  Kong, Norman ^a,b   Fotouhi, Nader ^a   Wovkulich, Peter M ^a   Roberts, John ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b Discovery Chemistry   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; 2 (4 AMINOCYCLOHEXYLAMINO) 6 (1 BENZYL 4 PIPERIDINYLAMINO) 9 CYCLOPENTYLPURINE; 6 CYCLOHEXYLMETHOXY 2 (4 SULFAMOYLANILINO)PURINE; 7 HYDROXYSTAUROSPORINE; BMS 310705; BMS 387042; CARBOPLATIN; CELL CYCLE PROTEIN; CHECKPOINT KINASE 1 INHIBITOR; CISPLATIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLINE; DOCETAXEL; ENZYME INHIBITOR; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; FLAVOPIRIDOL; GEMCITABINE; GW 491619; IRINOTECAN; ISPINESIB; IXABEPILONE; JNJ 7706621; KINESIN INHIBITOR; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PACLITAXEL; PNU 252808; RO 317453; ROSCOVITINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ASTHENIA; CANCER; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CELL VIABILITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL RESEARCH; CONTROLLED STUDY; DIARRHEA; DRUG MECHANISM; DRUG RESEARCH; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SUBUNIT; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INHIBITION KINETICS; NAUSEA; NONHUMAN; ORTHOSTATIC HYPERTENSION; PHASE TRANSITION; REGULATOR GENE; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; VOMITING;

EID: 0346993724     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2003.028.09.761413     Document Type: Review

References (143)

1. Li, Q., Sham, H.L. Discovery and development of antimitotic agents that inhibit tubulin polymerisation for the treatment of cancer. Expert Opin Ther Patents 2002, 12: 1663-702.
2. Borzilleri, R.M., Vite, G.D. Epothilones: New tublin polymerization agents in preclinical and clinical development. Drugs Fut 2002, 27: 1149-63.
3. Wartmann, M., Altmann, K.-H. The biology and medicinal chemistry of epothilones. Curr Med Chem Anti-Cancer Agents 2002, 2: 123-48.
4. Fotouhi, N., Ahmad, M., Banner, B. et al. Bis-indolyl maleimides as cell cycle inhibitors: Synthesis, structure-activity relationship, and preclinical evaluation of the development candidate, RO 31-7453. 223rd ACS Natl Meet (April 7-11, Orlando) 2002, Abst MEDI-145.
5. Johnson, R.K., Mccabe, F.L., Cauder, E. et al. SB-715992, a potent and selective inhibitor of KSP mitotic kinesin, demonstrates broad-spectrum activity in advanced murine tumors and human tumor xenografts. Proc Am Assoc Cancer Res 2002, 93: Abst 1335.
6. Sherr, C.J. Cancer cell cycle. Science 1996, 274: 1672-7.
7. Harper, J.W., Adams, P.D. Cyclin-dependent kinases. Chem Rev 2001, 101: 2511-26.
8. Pines, J. Cyclins: Wheels within wheels. Cell Growth Diff 1991, 2: 305-10.
9. Rechsteiner, M., Rogers, S.W. PEST sequences and regulator by proteolysis. Trend Biochem Sci 1996, 21: 267-71.
10. Glotzer, M., Murray, A.W., Kirschner, M.W. Cyclin is degraded by the ubiquitin pathway. Nature 1991, 349: 132-8.
11. Senderowicz, A.M., Sausville, E.A. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000, 92: 376-87.
12. Draetta, G., Eckstein, J. Cdc25 protein phosphatases in cell proliferation. Biochim Biophys Acta 1997, 1332: M53-63.
13. Mani, S., Wang, C., Wu, K. et al. Cyclin-dependent kinase inhibitors: Novel anticancer agents. Expert Opin Investig Drugs 2000, 9: 1849-70.
14. Hinds, P.W. CDK2 dethroned as master of S phase entry. Cancer Cell 2003, 3: 305-7.
15. 1 cyclin-dependent kinases and cancers. Cancer Metastasis Rev 2003, 22: 435-49.
16. Sausville, E.A. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med 2002, 8: s32-7.
17. Sielecki, T.M., Boylan, J.F., Benfield, P.A. et al. Cyclin-dependent kinase inhibitors: Useful targets in cell cycle regulation. J Med Chem 2000, 43: 1-18.
18. Fry, D.W., Garrett, M.D. Inhibitors of cyclin-dependent kinases as therapeutic agents for the treatment of cancer. Curr Opin Oncol Endocrine Metab Invest Drugs 2000, 2: 40-59.
19. Fisher, P.M. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors. Curr Opin Drug Discov Dev 2001, 4: 623-34.
20. Knockaert, M., Greengard, P., Meijer, L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002, 23: 417-25.
21. Rosania, G., Chang, Y-T. Targeting hyperproliferative disorders with cyclin-dependent kinase inhibitors. Expert Opin Ther Patents 2000, 10: 215-30.
22. Toogood, P.L. Progress toward the development of agents to modulate the cell cycle. Curr Opin Chem Biol 2002, 6: 472-8.
23. Fisher, P.M., Gianella-Borradori, A. CDK inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 2003, 12: 955-70.
24. Sausville, E.A. Cyclin-dependent kinase modulators studied at the NCI: Pre-clinical and clinical studies. Curr Med Chem Anti-Cancer Agents 2003, 3: 47-56.
25. Grant, S., Roberts, J.D. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Drug Resist Updates 2003, 6: 15-26.
26. Senderowicz, A.M. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms. Cancer Chemother Pharmacol 2003, 52(s01): 61-73.
27. Dai, Y., Grant, S. Cyclin-dependent kinase inhibitors. Curr Opin Pharmacol 2003, 3: 362-70.
28. Huwe, A., Mazitschek, R., Giannis, A. Small molecules as inhibitors of cyclin-dependent kinases. Angew Chem Int Ed 2003, 42: 2122-38.
29. Vermeulen, K., Van Bockstaele, D.R., Berneman, Z.N. The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003, 36: 131-49.
30. Filgueira de Azevedo, W. Jr., Canduri, F., Freitas da Silveira, N.J. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem Biophys Res Commun 2002, 293: 566-71.
31. Kim, K.S., Sack, J.S., Tokarski, J.S. et al. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: Synthesis and biological effects. J Med Chem 2000, 43: 4126-34.
32. Carlson, B., Lahusen, T., Singh, S. et al. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 1999, 59: 4634-41.
33. Patel, V., Senderowicz, A.M., Pinto, D. et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 1998, 102: 1674-81.
34. Schrump, D.S., Matthews, W., Chen, G.A. et al. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Clin Cancer Res 1998, 4: 2885-90.
35. Pepper, C., Thomas, A., Hoy, T. et al. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. Br J Haematol 2001, 114: 70-7.
36. Sedlacek, H.H. Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol 2001, 38: 139-70.
37. Brusselbach, S., Nettelbeck, D.M., Sedlacek, H.H. et al. Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells. Int J Cancer 1998, 77: 146-52.
38. Kerr, J.S., Wexler, R.S., Mousa, S.A. et al. Novel small molecule alpha v integrin antagonists: Comparative anti-cancer efficacy with known angiogenesis inhibitors. Anticancer Res 1999, 19: 959-68.
39. Melillo, G., Sausville, E.A., Cloud, K. et al. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res 1999, 59: 5433-7.
40. Raju, U., Nakata, E., Mason, K.A. et al. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Cancer Res 2003, 63: 3263-7.
41. Gojo, I., Zhang, B., Fenton, R.G. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 2002, 8: 3527-38.
42. Czech, J., Hoffmann, D., Nair, R. et al. Antitumor activity of flavone L86-8275. Int J Oncol 1995, 6: 31-6.
43. Arguello, F., Alexander, M., Sterry, J.A. et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 1998, 91: 2482-90.
44. Kelland, L.R. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: Current status. Expert Opin Investig Drugs 2000, 9: 2903-11.
45. Zhai, S., Senderowicz, A.M., Sausville, E.A. et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clincal development. Ann Pharmacother 2002, 36: 905-11.
46. Tan, A.R., Swain, S.M. Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy. Semin Oncol 2002, 29 (3, Suppl. 11): 77-85.
47. Burdette-Radoux, S., Tozer, R.G., Lohmann, R. et al. NCIC CTC phase II study of flavopiridol in patients with previously untreated metastatic malignant melanoma (IND. 137). Proc Am Soc Clin Oncol 2002, 21: Abst 1382.
48. Tan, A., Headlee, D., Messmann, R. et al. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1 hour infusion in patients with advanced neoplasms. J Clin Oncol 2002, 20: 4074-82.
49. Schwartz, G.K., O'Reilly, E., Ilson, D. et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002, 20: 2157-70.
50. Tan, A.R., Zhai, S., Berman, A.S. et al. Phase I trial of docetaxel followed by infusion flavopiridol over 72h in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2002, 21: Abst 1955.
51. Kassimis, B., Rocha-Lima, C., Cogswell, J.J. et al. Phase I study evaluating 1-hour flavopiridol (HMR1275) in combination with docetaxel (D) in previously treated non-small cell lung cancer (NSCLC) patients (pts). Proc Am Soc Clin Oncol 2003, 22: Abst 2689.
52. Bible, K.C., Lensing, J.L., Nelson, S.A. et al. A phase I trial of flavopiridol combined with cisplatin in patients with advanced malignancies. Proc Am Assoc Cancer Res 2002, 93: Abst 2749.
53. Shah, M.A., Kortmansky, J., Gonen, M. et al. A phase I/pharmacologic study of weekly sequential irinotecan (CPT) and flavopirldol (F). Proc Am Soc Clin Oncol 2002, 21: Abst 373.
54. Gries, J-M., Kasimis, B., Schwarzenberger, P. et al. Phase I study of HMR1275 (flavopiridol) in non-small cell lung cancer (NCSLC) patients after 24hr IV administration in combination with paclitaxel and carboplatin. Proc Am Soc Clin Oncol 2002, 21: Abst 372.
55. Schoepfer, J., Fretz, H., Chaudhuri, B. et al. Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics. J Med Chem 2002, 45: 1741-7.
56. Haesslein, J-I., Lefrancois, D., Uridat, E. et al. Preparation of flavone derivatives for use as medicines. WO 0164673.
57. McClue, S.J., Blake, D., Clarke, R. et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002, 102: 463-8.
58. Raymond, E., Laurence, V., Faivre, S. et al. Preliminary results of an ongoing phase I and pharmacokinetic study of CYC 202, a novel oral cyclin-dependent kinase inhibitor in patients with advanced malignancies. AACR NCI EORTC Mol Targets Cancer Ther 2002, Abst 150.
59. De Azevedo, W.F., Leclerq, S., Meijer, L. et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 1997, 243: 518-26.
60. Hardcastle, I.R., Golding, B.T., Griffin, R.J. Designing inhibitors of cyclin-dependent kinases. Annu Rev Pharmacol Toxicol 2002, 42: 325-48.
61. Davies, T.G., Bentley, J., Arris, C.E. et al. Structure-based design of a potent purine-based cyclin dependent kinase inhibitor. Nat Struct Biol 2002, 9: 745-9.
62. Shum, P.W., Peet, N.P., Weintraub, P.M. et al. The design and synthesis of purine inhibitors of CDK2. III. Nucleosides, Nucleotide Nucleic Acids 2001, 20: 1067-78.
63. Dickerson, S.H., Drewry, D.H. Preparation of pyrrolo[3,2-f]quinolin-2-ones as CDK4 inhibitors. WO 0220524.
64. Eberwein, D.J., Harrington, L., Griffin, R. et al. Biological evaluation of GW-491619, a novel substituted oxindole CDK4 ser/thr inhibitor. Proc Am Assoc Cancer Res 2002, 93: Abst 1611.
65. Riou, J-F., Maratrat, M., Grondard, L. et al. CDK-1 inhibitor arylideneoxindoles. WO 0268411.
66. Liu, J.-J., Dermatakis, A., Lukacs, C. et al. 3,5,6-Trisubstituted naphthostyrils as CDK2 inhibitors. Bioorg Med Chem Lett 2003, 13: 2465-8.
67. Li, X., Huang, P., Cui, J.J. et al. Novel pyrrolyllactone and pyrrolyllactam indolinones as potent cyclin-dependent kinase 2 inhibitors. Bioorg Med Chem Lett 2003, 13: 1939-42.
68. Pevarello, P., Orsini, P., Traquandi, G. et al. Preparation of 5-cycloalkyl-3-(phenylacetamido)-1H-pyrazole cdk inhibitors as antitumor agents. WO 0248114.
69. Reich, S.H., Wallace, M.B. Pyrazoles for inhibiting protein kinase. WO 0179198.
70. Chong, W.K.M., Duvadie, R.K. Preparation of 5-amino-3-substituted-pyrazolo[4,5-d]thiazole compounds as inhibitors of cyclin-dependent kinases. WO 0212250.
71. Misra, R.N., Xiao, H., Rawlins, D.B. et al. 1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases: Highly potent 2,6-difluorophenyacyl analogues. Bioorg Med Chem Lett 2003, 13: 2405-8.
72. Kania, R.S., Bender, S.L. Borchardt, A.J. et al. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use. WO 0102369.
73. Lee, J.H., Hong, C.Y., Park, T.S. et al. Preparation of indazoles substituted with 1,1-dioxoisothiazolidine as inhibitors of cell proliferation. WO 0185726.
74. Ding, Q., Liu, J.-J., Madison, V. S. et al. Preparation of pyrazolobenzodiazepines as CDK2 inhibitors. WO 0064900.
75. Nugiel, D.A., Etzkorn, A-M., Vidwan, A. et al. Indenopyrazoles as novel cyclin-dependent kinase inhibitors. J Med Chem 2001, 44: 1334-6.
76. Nugiel, D.A., Vidwan, A., Etzkorn, A-M. et al. Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 2. Probing the indeno ring substituent pattern. J Med Chem 2002, 45: 5224-32.
77. Yue, E.W., Higley, C.A., DiMeo, S.V. et al. Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3. J Med Chem 2002, 45: 5233-48.
78. Arris, C.E., Boyle, F.T., Calvert, A.H. et al. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J Med Chem 2000, 43: 2797-804.
79. Mesguiche, V., Parsons, R.J., Arris, C.E. et al. 4-Alkoxy-2,6-diaminopyrimidine derivatives: Inhibitors of cyclin dependent kianses 1 and 2. Bioorg Med Chem Lett 2003, 13: 217-22.
80. Thomas, A.P. 4-Amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell cycle inhibitors. WO 0172717.
81. Sayle, K.L., Bentley, J., Boyle, F.T. et al. Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 1 and 2. Bioorg Med Chem Lett 2003, 13: 3079-82.
82. Wu, S.Y., McNae, I., Kontopidis, G. et al. Structural basis for ligand-induced disordering of the activation loop. Structure 2003, 11: 399-10.
83. Wang, S., Blake, D., Clarke, R. et al. 4-Heteroaryl-2-phenylamino-pyrimidine, a new class of CDK2 inhibitors: Discovery, optimisation, and anti-proliferative activity in vitro and in vivo. Proc Am Assoc Cancer Res 2002, 93: Abst 4202.
84. Wang, S., Meades, C., Wood, G. et al. N-(4-(4-Methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds. WO 0329248.
85. Wang, S., Anderson, S., Clarke, R. et al. Optimization and evaluation of substituted 2-phenylamino-4-(thiazol-5-yl)-pyrimidine CDK inhibitors as oral anti-cancer drug candidates. Proc Am Assoc Cancer Res 2003, 94: Abst 3974.
86. Anderson, M., Beattie, J.F., Breault, G.A. et al. Imidazo[1,2-a]pyrimidines: A potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation. Bioorg Med Chem Lett 2003, 13: 3021-6.
87. Harris, P.A., Jung, D.K., Peel, M.R. et al. Preparation of (pyrazolo[1,5-b]pyridazinyl)pyrimidinamines and analogs as cyclin dependent kinase inhibitors for treatment of cancer. WO 0351886.
88. Breault, G.A., Ellston, R.P.A., Green, S. et al. Cyclin-dependent kinase 4 inhibitors as treatment for cancer. Part 2: Identification and optimization of substituted 2,4-bisanilino pyrimidines. Bioorg Med Chem Lett 2003, 13: 2961-6.
89. Kim, K.S., Kimball, S.D., Mirsa, R.N. et al. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: Synthesis, x-ray crystallographic analysis, and biological activities. J Med Chem 2002, 45: 3905-27.
90. Mirsa, R.N., Xiao, H-Y., Kim, K.S. et al. BMS-387032: A selective Cdk2 inhibitor with potent antitumor activity. 225th ACS Natl Meet (March 23-27, New Orleans) 2003, Abst MEDI 18.
91. Lee, F. Y.F., Camuso, A., Clark, J. et al. BMS-387032, a selective inhibitor of cyclin-dependent kinase 2 with potent antitumor activity in vivo. Proc Am Assoc Cancer Res 2003, 94: Abst 958.
92. Wong, T.W., Kimball, D., Misra, R.N. et al. BMS-387032, a potent and selective inhibitor of cyclin-dependent kinase 2, induces cell cycle arrest and apoptosis in human tumor cells. Proc Am Assoc Cancer Res 2003, 94: Abst 3125.
93. Misra, R.N., Xiao, H-X., Barbosa, S.A. et al. Synthesis, SAR and solid-state structure of BMS-387032: A potent and selective CDK2 inhibitor with anti-tumor activity. Proc Am Assoc Cancer Res 2003, 94: Abst 3976.
94. Misra, R.N., Xiao, H-Y., Kim, K.S. et al. Discovery and development of acyl-2-aminothiazole cyclin-dependent kinases with potent in vivo activity. 223rd ACS Natl Meet (April 7-11, Orlando) 2002, Abst MEDI 251.
95. Ciomei, M., Albanese, C., Rossi, R. et al. The CDK2/cyclin A inhibitor PNU-252808 blocks cell cycle progression and induces apoptosis in tumor cells both in vitro and in vivo. Proc Am Assoc Res 2001, 92: Abst 2179.
96. Latham, V.M., Shapiro, G.I. Selective inhibition of cyclin-dependent kinase (cdk)2 by PNU252808 induces cell cycle arrest, apoptosis and cytotoxic synergy with DNA-damaging agents in non-small cell lung cancer cell lines. Proc Am Assoc Cancer Res 2003, 94: Abst 2778.
97. DePinto, W.E., Yin, X., Smith, M. et al. The in vitro and in vivo effects of small molecule inhibitors of cyclin dependent kinase 4. Proc Am Assoc Cancer Res 2003, 94: Abst 3126.
98. Chu, S.S., Alegria, L.A., Bleckman, T.M. et al. Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, methods for their use. WO 0304467.
99. Honma, T., Hayashi, K., Aoyama, T. et al. Structure-based generation of a new class of potent cdk4 inhibitors: New de novo design strategy and library design. J Med Chem 2001, 44: 4615-27.
100. Honma, T., Yoshizumi, T., Hashimoto, N. et al. A novel approach for the development of selective cdk4 inhibitors: Library design based on locations of cdk4 specific amino acid residues. J Med Chem 2001, 44: 4628-40.
101. Hirai, H., Fukasawa, K., Machida, T. et al. Effects of a novel, diarylurea class of cdk4 selective inhibitor on the progression of mammalian cell cycle. Proc Am Assoc Cancer Res 2001, 92: Abst 4870.
102. Denny, W.A., Dobrusin, E.M., Kramer, J.B. et al. Preparation of pteridinones as kinase inhibitors. WO 0119825.
103. Engler, T.A., Furness, K.W., Malhotra, S. et al. Preparation and use of indolo-pyrrolo-carbazole derivatives as inhibitors of cdk4 kinase and methods for treating proliferative diseases. WO 0228861.
104. Brooks, H., Watkins, S.A., Spencer, C.D. et al. Indolocarbazoles as cyclin D1/cdk4 inhibitors. Proc Am Assoc Cancer Res 2002, 93: Abst 1610.
105. Engler, T.A., Furness, K., Malhotra, S. et al. Novel, potent and selective cyclin D1/CDK4 inhibitors: Indolo[6,7-a]pyrrolo[3,4-c]carbazoles. Bioorg Med Chem Lett 2003, 13: 2261-7.
106. Zhu, G., Conner, S.E., Zhou, X. et al. Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J Med Chem 2003, 46: 2027-30.
107. Emanuel, S.L., Gruninger, R., Lin, R. et al. Inhibition of human tumor xenograft growth by a novel, potent and selective CDK inhibitor. Proc Am Assoc Cancer Res 2003, 94: Abst 707.
108. Sampath, D., Plunkett, W. Design of new anticancer therapies targeting cell cycle checkpoint pathways. Curr Opin Oncol 2001, 13: 484-90.
109. Sagata, N. Untangling checkpoints. Science 2002, 298: 1905-7.
110. Mailand, N., Falck, J., Lukas, C. et al. Rapid destruction of human Cdc25A in response to DNA damage. Science 2000, 288: 1425-9.
111. Falck, J., Mailand, N., Syljuasen, R.G. et al. The ATM-chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001, 410: 842-7.
112. 2 checkpoints. Proc Natl Acad Sci USA 2002, 99: 14795-800.
113. 2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem 2003, 278: 21767-73.
114. Falck, J., Pertrini, J.H.J., Williams, B.R. et al. The DNA damage-dependent intra-S phase checkpoint is regulated by parallel pathways. Nat Genet 2002, 30: 290-4.
115. Matsuoka, S., Huang, M., Elledge, S.J. Linkage of ATM to cell cycle regulation by the chk2 protein kinase. Science 1998, 282: 1893-7.
116. Sanchez, Y., Wong, C., Thomas, R.S. et al. Conservation of the chk1 checkpoint pathway in mammals: Linkage of DNA damage to cdk regulation through Cdc25. Science 1997, 277: 1497-501.
117. 2/M events by Cdc25A through phosphorylation-dependent modulation of its stability. EMBO J 2002, 21: 5911-20.
118. Hurley, L.H. DNA and its associated processes as targets for cancer therapy. Nature 2002, 2: 188-200.
119. Bartek, J., Lukas, J. Chk1 and chk2 kinases in checkpoint control and cancer. Cancer cell 2003, 3: 421-9.
120. 2/M DNA damage checkpoint. Genes Dev 2000, 14: 1448-59.
121. 2 checkpoint abrogators. Curr Med Chem Anti-Cancer Agents 2003, 3: 35-46.
122. Li, Q., Zhu, G-D. Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer. Curr Topics Med Chem 2002, 2: 938-71.
123. Akinaga, S., Sugiyama, K., Akiyama, T. UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: A new generation of anti-cancer agents for the new century? Anticancer Drug Des 2000, 15: 43-52.
124. Graves, P.R., Yu, L., Schwarz, J.K. et al. The chk1 protein kinase and the cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000, 275: 5600-5.
125. Zhao, B., Bower, M.J., McDevitt, P.J. et al. Structural basis for chk1 inhibition by UCN-01. J Biol Chem 2002, 277: 46609-15.
126. 1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitors p21/cip1/waf1/Sdi1 in p53 mutated human epidermoid carcinoma A431 cells. Cancer Res 1997, 57: 1495-501.
127. Sato, S., Fujita, N., Tsuruo, T. et al. Interference with PDK-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 2002, 21: 1727-38.
128. Facchinetti, M.M., De Siervi, A., Toskos, D. et al. Cell cycle arrest by UCN-01 requires transcriptional activation of p21. Proc Am Assoc Cancer Res 2003, 94: Abst 2790.
129. Busby, E.C., Leistritz, D.F., Abraham, R.T. et al. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hchk1. Cancer Res 2000, 60: 2108-12.
130. Kohn, E.A., Ruth, N.D., Brown, M.K. et al. Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. J Biol Chem 2000, 277: 26553-64.
131. Sausville, E.A., Arbuck, S.G., Messmann, R. et al. Phase I trial of 72-hour continuous infusion UCN-01 in patient with refractory neoplasms. J Clin Oncol 2001, 19: 2319-33.
132. Shaw, V.A., Rini, B.I., Park, J.W. et al. A phase 2 study of UCN-01 in advanced renal cell carcinoma. Proc Am Soc Clin Oncol 2003, 22: Abst 1775.
133. Hakimian, R.R., Edelman, M.J., Bauer, K. Phase I and pharmacokinetic (PK) study of the cyclin dependent kinase (CDK) inhibitor UCN-01 and carboplatin in solid tumors. Proc Am Soc Clin Oncol 2003, 22: Abst 598.
134. Gandara, D.R., Lara, P.N., Longmate, J. et al. The cyclin-dependent kinase (CDK) inhibitor UCN-01 plus cisplatin in advanced solid tumors: A California Cancer Consortium phase I trial. Proc Am Soc Clin Oncol 2003, 22: Abst 987.
135. Hotte, S.J., Hirte, H.W., Oza, A. et al. Early results of a phase I study of topotecan (T) in combination with the novel kinase inhibitor UCN-01 in patients with advanced cancer. Proc Am Assoc Cancer Res 2003, 94: Abst 5355.
136. 2 cell cycle checkpoints. Cancer Res 2003, 63: 31-5.
137. Keegan, K.S., Kesicki, E.A., Gaudino, J.J. et al. Aryl and heteroaryl urea chk1 inhibitors for use as radiosensitizers and chemosensitizers. WO 0270494.
138. Stavenger, R.A., Witherington, J., Rawlings, D.A. et al. Preparation of N-pyrrolopyridinyl carboxamides as chk1 kinase inhibitors for treating various forms of cancer and hyperproliferative disorders. WO 0328724.
139. Parrish, C.A., Callahan, J.F., Li, Y. et al. Preparation of 2-ureidothiophenes as angiogenesis and chk1 kinase inhibitors for treating various forms of cancer and hyperproliferative disorders. WO 0329241.
140. Parrish, C.A., Callahan, J.F., Wan, Z. et al. Preparation of 3-ureidothiophenes as angiogenesis and chk1 inhibitors for treating various forms of cancer and hyperproliferative disorders. WO 0328731.
141. Lin, N-H., Sham, H.L., Xia, P. Preparation of 3-heteroaryl-methylene-1,3-dihydro-2H-indol-2-ones as protein kinase inhibitors. WO 0351838.
142. Tetsu, O., McCormick, F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003, 3: 233-45.
143. Geng, Y., Yu, Q., Sicinska, E. et al. Cyclin E ablation in the mouse. Cell 2003, 114: 431-43.